4. Eli Lilly

Eli Lilly
Eli Lilly has scored eight drug approvals in the last five years, including its breast cancer drug Verzenio, which carries a net present value of $17 billion.

Eli Lilly 
Approvals in past 5 years:
Value of recent approvals: $38.05 billion 
Percent of value from recent approvals: 36% 

Several years back, Eli Lilly was among the Big Pharma companies most reliant on older drugs in its portfolio. The company has made serious strides to change that in the more recent past. 

Now, Eli Lilly is among the top players in the industry getting the most value from its new launches, data from EvaluatePharma and Evaluate Vantage show. The company’s entire portfolio is worth $105 billion at net present value, and 36% of the total comes from launches within the last five years, the analysts say. Those new drugs are worth about $38 billion.

Since 2016, Lilly has nabbed eight new FDA approvals, trailing only Novartis and Merck on that metric and tying Roche. Lilly's new launches include immunology blockbuster Taltz, with a net present value of $9.8 billion, and the breast cancer drug Verzenio, with its impressive net present value figure of $17.13 billion.  

RELATED: The top 15 pharma companies by 2026 sales — Eli Lilly 

Perhaps more than its peers, Eli Lilly has worked to refocus itself around new meds in recent years. During each quarterly earnings report, the company lists the proportion of its sales that came from its “key growth products.” In recent quarters, these meds have generated about half of the company’s overall sales.

Its second-quarter filing shows that this group of products, which includes the eight medicines in Evaluate Pharma's list and others approved more than five years ago—such as diabetes blockbuster Trulicity—generated 54%.

As for drugs approved in recent years, the Evaluate tally also includes rheumatoid arthritis drug Olumiant, which has earned some sales in COVID-19 thanks to positive data leading to an FDA emergency use authorization. That drug’s net present value is $2.58 billion, Evaluate says. 

But not all of Lilly's launches were winners. Lartruvo, the 2016 sarcoma launch that the company pulled from the market in 2019 after it failed a confirmatory trial, carries a net present value of $0, Evaluate analysts say. As does the Alzheimer’s diagnostic agent Tauvid.

Reyvow, the company’s 2019 migraine approval, carries a modest $310 million in net present value, the Evaluate data show. That drug hasn’t been able to keep pace with other new migraine launches from Biohaven and AbbVie, and Lilly didn’t list its sales as material in its second-quarter earnings report. 

RELATED: Lilly gears up for 'top-tier' growth to 2025 thanks to its new launches 

Meanwhile, the company had a strong run with COVID-19 antibodies, but variants have proved to be a serious challenge for the company's pandemic offerings. After generating more than $1.5 billion last year and earlier this year, Lilly's antibodies bamlanivimab and etesevimab have largely ceded the key U.S. market to Regeneron’s rival meds. Those drugs aren't included in Evaluate's industrywide R&D analysis.

Thanks to Lilly’s new launches—and the fact that the company doesn't expect major patent expirations in the coming years—executives said in early 2020 that the drugmaker is gearing up for “top-tier” growth among its rivals out to 2025.

4. Eli Lilly